Introduction
Coronary obstruction is a life-threatening complication of transcatheter aortic valve replacement (TAVR), and it is commonly secondary to displacement of a valve leaflet towards the coronary ostia. 1, 2 We have recently conducted a multicentre registry on coronary obstruction showing that this is a rare (incidence < 1%) but life-threatening complication following TAVR. Specific anatomic factors such as low-lying coronary ostium and shallow sinus of Valsalva (SOV) were associated with this complication. 1,2 Also, coronary obstruction was much more frequent during TAVR for degenerative bioprosthetic valves ('valve-invalve'-ViV). 2 However, the number of ViV cases was limited, precluding a thorough evaluation of this complication in such patients. Transcatheter heart valve (THV) implantation inside failed aortic surgically implanted bioprosthetic valves represents an appealing less invasive alternative to reoperation, with growing indication worldwide. Of note, the Valve-in-Valve International Data (VIVID) Registry, which is the largest evaluation of ViV to date, has also revealed a much higher rate of coronary obstruction as compared with native aortic valves (four-fold greater), in accordance to the aforementioned reports. [3] [4] [5] Nonetheless, prior studies presented limited number of ViV cases suffering this complication without any comparison against a control group, preventing the determination of its exact incidence, in function of the different surgically implanted bioprosthetic valves, associated factors and outcomes. The objectives of the present study were therefore to evaluate the baseline characteristics, predictive factors, and clinical outcomes of coronary obstruction as a complication of TAVR in patients with prior surgically implanted aortic bioprosthesis.
Methods

Registry design
The VIVID Registry is a global data collection of ViV procedures, including different THV devices and valve positions. 4 Since 2010, the registry prospectively collects data from centres in Europe, North America, South America, Africa, Oceania, and the Middle East. Data collection is performed using dedicated case report forms. In the following analysis, all of the cases from April 2007 until May 2016 were included, though patients undergoing ViV in non-aortic positions were excluded. No restriction to the THV or aortic bioprosthesis type and size were considered. The patients presenting coronary obstruction were compared with those without coronary obstruction and served as controls. Inconsistencies were resolved directly with local investigators and on-site data monitoring. All patients gave written informed consent to the transcatheter aortic ViV procedures.
Definitions
All information on clinical presentation, diagnosis, and treatment of the coronary obstruction complication, as well as 30-day and late clinical outcomes were entered. The clinical events were defined according to the VARC-2 criteria. 6 The mechanism of bioprosthetic valve degeneration (i.e. regurgitation, stenosis, or combined) was evaluated using criteria set by previous guidelines. 7, 8 Patients with at least a moderate degree of both stenosis and regurgitation were included in the combined group. Other patients were categorized according to the primary mechanism of degeneration, either stenosis or regurgitation.
Computed tomography
Centralized core laboratory assessment of the computed tomography (CT) from 20 patients with coronary obstruction and 90 consecutive controls from 2 centres were performed by two experienced operators blinded to all clinical results (St. Paul's Hospital, Vancouver, Canada). The main baseline bioprosthetic valve characteristics of the patients in the control group with and without CT data are shown in Supplementary material online, Table S1 . In addition, the main baseline characteristics between patients with CT data pre-TAVR with and without coronary obstruction are shown in Supplementary material online, Table S2 . The CT measurements included the surgical frame mean diameter and area, coronaries height in relation to aortic annulus, aortic annulus diameter and area, SOV width, and the diameter of the sinotubular junction. The coronary artery heights were measured relative to basal ring of the prosthetic valve. Likewise, we sought to validate the previously described Vancouver 5, 9 for predicting the risk of coronary occlusion as determined by the distance between a virtual transcatheter valve, at a size of the implanted device, towards each coronary ostium in both groups (VTC; Figure 1 ). Essentially, the VTC is obtained by identifying the basal ring plane and the geometric centre of the surgical valve. Then, a virtual cylinder with the estimated nominal size of the THV (i.e. a 26 mm THV leads to a cylinder with the same height of the THV and a 26 mm diameter) is placed in the middle of the basal ring. The centres of the basal ring and of the cylinder are aligned. Finally, the horizontal distance between the edge of the cylinder and the ostia of the coronary arteries is measured with a caliper measurement tool of the CT imaging software. The anticipated area of the THV was estimated by the circle area formula: pR
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, where the radius (R) is obtained dividing the diameter of the device by 2. Therefore, in the case of self-expanding devices such as the CoreValve the worst-case scenario was used. 9 
Results
Of 1612 patients who underwent a ViV procedure in 135 centres worldwide, a total of 37 cases (2.3%) of symptomatic coronary obstruction occurred following THV implantation. The incidence of coronary obstruction according to the type of surgically implanted bioprostheses is shown in Figure 2 , while its distribution with respect to the type of transcatheter valve, approach, and mechanism of bioprosthetic surgical valve failure is shown in Supplementary material online, Figure S1 . A higher incidence of this complication was only seen with regards to the type of bioprosthesis. The main baseline characteristics of the study population, according to the occurrence of coronary obstruction, are shown in Table 1 . Patients who suffered symptomatic coronary obstruction presented similar baseline clinical characteristics with respect to controls, apart from the differences in the type of surgically implanted bioprostheses. In addition, CABG was less frequent in those with coronary obstruction in relation to controls (P = 0.05). The main procedural and 30-day outcomes are shown in Table 2 . The procedural variables were similar between both groups, except for a trend towards a higher rate of postdilatation in the coronary obstruction group (22.2% vs. 12.7%, respectively; P = 0.07). At 30 days, death rate was much higher in this group vs. controls (48.6% vs. 3.7%; P < 0.001).
Computed tomography data
Pre-TAVR CT data were available in 20 of the 37 patients with coronary obstruction (54%). CT data of the patients with coronary obstruction in relation to the control group are shown in Table 3 .
Patients with coronary obstruction exhibited a smaller SOV diameter (27.44 ± 4.05 vs. 32.55 ± 3.98; P < 0.001). In addition, although the coronary artery heights with respect to the annulus were similar between both groups, the VTC distance to the left and right coronary arteries [left coronary artery (LCA) and right coronary artery (RCA), respectively] were much shorter in the coronary obstruction group in relation to controls (P < 0.001 for both).
Predictors of coronary obstruction
The main predictors of coronary obstruction are shown in Table 4 .
Using multivariable analysis, the use of a stentless or stented bioprosthesis with externally mounted leaflets (OR: 7.67; 95% CI: 3.14-18.7; P < 0.001) was an independent predictor of coronary obstruction in the overall population. Likewise, when including only the patients with a CT pre-TAVR, the multivariable analysis showed that the VTC was the only predictor of coronary obstruction (OR: 0.22 per 1 mm increase; 95% CI 0.09-0.51; P < 0.001), even after adjusting for SOV width. In addition, the SOV width presented significant collinearity with the VTC (R 2 = 0.688, P < 0.001; Supplementary material online, Figure   S2 ). A VTC cut-off value of 4 mm best identified those patients at higher risk for coronary obstruction (area under the curve: 0.943 [0.893-0.991]; sensitivity = 85%, specificity = 89%; P < 0.001). The distribution of the VTC relative to the LCA and RCA ostia is shown in Figure 3 for both groups.
Clinical presentation and management
Data on clinical presentation and management of coronary obstruction were available for 36 patients (97% of the population), as shown in Table 5 . Coronary obstruction occurred at the ostium of the LCA in most cases (91.7%) either alone or in association with RCA occlusion, and the diagnosis was made by coronary angiography in all but one patient. Coronary obstruction was related to the displacement of bioprosthetic valve leaflet towards the coronary ostium in all patients, and occurred most frequently immediately after valve implantation (58.3%). Still, it occurred within days following the procedure in 36.1% of the patients (76.9% of the time with selfexpandable devices). Most cases (58.3%) presented with severe persistent hypotension or electrocardiographic (ECG) changes (52.8%), mainly driven by ST-segment deviation and ventricular arrhythmias. Coronary revascularization with percutaneous coronary intervention (PCI) was not attempted in eight patients (22.2%). One patient died within the few minutes following a complete left coronary obstruction with insufficient time for any coronary revascularization attempt; in four patients the occlusion occurred within the hours following the procedure with no time for PCI; one patient went directly to urgent CABG; in one patient the obstruction occurred after pre-dilatation, with temporary occlusion of the LMS and subsequent abandoning of the procedure; and in one patient a repositionable valve allowed the relief of the obstruction by retrieving the device (Lotus valve). PCI was attempted in 28 patients (77.8%), and it was successful (residual stenosis < 20% and TIMI flow 3) in 64.3% of attempted procedures. Revascularization failures by PCI were mainly due to wire crossing failure (50%) or cannulation failure (30%). A total of three patients underwent urgent coronary artery bypass graft, and in two patients occurring after PCI failure. A total of 13 patients (36.1%) required haemodynamic support.
Procedural death occurred in 8 patients (22.2%), and among those patients who survived the procedure 10 additional patients died within 30 days, all of them related to the periprocedural complications, leading to a 30-day mortality rate of 48.6% (18 patients). Among the patients with PCI failures, 80% died within 30 days. In patients with coronary obstruction, the echocardiographic data showed a mean residual gradient of 11.1 ± 5.2 mmHg, aortic valve area of 1.46 ± 0.47 cm 2 , with no patients presenting with more than mild aortic regurgitation. These results were similar as compared with the controls. As shown in the Kaplan-Meier curve the 1-year survival rate was 47.8% in the coronary obstruction group (Figure 4) . At a median follow-up of 460 days (IQR 361-1014.25) among the survivors of the coronary obstruction group, the mean left ventricular ejection fraction was 55.9% ± 7.5 and 78.6% of the patients were in New York Heart Association class < _ 2.
Discussion
The main findings of the present study evaluating coronary obstruction as a complication of TAVR, in patients with prior surgically implanted aortic bioprosthesis, were as follows: (i) coronary obstruction following aortic ViV procedures is a life-threatening complication with high procedural and short-term mortality; (ii) coronary obstruction occurred more frequently in patients with prior stentless or stented with externally mounted leaflets bioprostheses; (iii) short VTC as evaluated by CT (<4 mm) predicted this complication; and (iv) clinical presentation included most likely persistent severe hypotension and ST-segment changes, and although PCI may be attempted in the majority of the patients, haemodynamic support and conversion to open heart surgery were still required in a significant proportion of them, with more than half dying within 30 days following TAVR.
Coronary obstruction and valve-in-valve: incidence and associated factors
The risks of coronary obstruction following TAVR have been stressed since the first experimental and clinical experiences, [10] [11] [12] and it was first reported in the context of ViV procedures in 2011. 13 Since then, the reported incidence of coronary obstruction has been higher during ViV procedures, reaching up to 3.5% of the patients, 3 as opposed to systematically <1% in native aortic valves. 1, 2 In the present study, including a large series of ViV- The mechanisms underlying coronary obstruction following ViV appear to be displacement of the bioprosthetic leaflet towards the coronary ostium in all patients, and no cases of coronary obstruction related to the struts of the transcatheter valve frame or to the cuff/ leaflets of the transcatheter valve itself were noted in the present study.
1,2 Also, according to prior smaller ViV studies, 4 this complication was more frequent with stented bioprostheses with externally mounted leaflets, and also with stentless bioprostheses, representing up to 80% of the obstructions. In externally mounted bioprostheses, the relatively long leaflets outside the stent, in comparison with internally mounted leaflets, may be the causative factor for a higher rate of coronary obstruction. 13 Furthermore, the stentless bioprostheses are usually implanted in a supra-annular position, resulting in a shorter distance of the coronary ostia take-off in relation to the valve leaflets, which in association with lack of stent posts, may facilitate the interaction of the prosthetic leaflet and the coronary ostia. Unlike prior studies in native aortic valves, no association of the transcatheter valve type with this complication was detected.
1,2 Also, we have noticed a higher rate of post-dilatation in the coronary obstruction group, even though this factor was not retained in the multivariable analysis. Of note, in a recent in vitro study with the SAPIEN XT THV implanted inside a Trifecta bioprosthesis (stented with externally mounted leaflet), the use of an undersized THV implantation successfully avoided coronary flow obstruction.
14 Future studies also may consider post-dilatation and relative THV sizing as predictors of coronary occlusion. In addition, our study is the first to confirm the Vancouver method of the VTC distance by CT as an important factor related to this complication.
5,9 Also, we were able to define a cut-off associated with an increased risk of this severe complication (<4 mm; area under the curve: 0.943 
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of the patients with CT data pre-TAVR and coronary obstruction had a VTC distance < 4 mm, supporting its inclusion in the workup prior to aortic ViV procedures. The SOV width was an important factor related to this complication in native valves. However, in the present study after adjusting for the VTC, this factor was not retained in the multivariable analysis. Most likely, the SOV presented a significant collinearity with respect to the VTC, and also it does not account for the occasional canted position of a slightly tilted and noncoaxial surgically implanted prosthesis. 5 Collectively, in those patients considered at high risk for coronary obstruction, it is reasonable to suggest the implementation of additional security measures during ViV procedures, such as coronary protection with a guidewire and an undeployed stent in the coronary artery. 1, 2, 15, 16 Finally, the use of a transcatheter valve that can be repositioned or retrieved in case of coronary obstruction following valve implantation should probably be recommended in such cases, although the occurrence of late coronary obstruction in up to onethird of the patients may mitigate such benefits.
Clinical presentation and management of coronary obstruction following valve-invalve
The majority of the patients presented with persistent severe hypotension and ST-segment changes immediately after valve implantation. This clinical presentation is explained by the fact that the LCA was obstructed in the majority of the patients either alone or in association with RCA occlusion, and this is in accordance with prior studies in the context of native aortic valves. 1, 2 Of note, the presence of persistent severe hypotension following valve implantation, and especially in conjunction with ECG changes, should prompt aortography and/or echocardiography to evaluate coronary flow abnormalities or new segmental abnormalities. In those cases where a pre-emptive coronary wire protection with or without stent placement were performed, prompt selective coronary injection may confirm the diagnosis and further expedite treatment with PCI. 16 In the present study, PCI was attempted in the majority of the patients, and was successful in most of them. Still, in up to one-third of patients, urgent CABG or mechanical support was required. Overall, the 30-day mortality rate was close to half of the patients, and it reached 80% of those patients with unsuccessful PCI. This even higher mortality rates as compared with native aortic valves (41%) 2, 3 underscores that these procedures should be performed in highly experienced centres with surgical capabilities, in order to potentially restore coronary flow by CABG in case of PCI failure. Also, as this complication may have delayed onset in a significant proportion of patients, especially with self-expandable devices (77% among late Figure 3 Distribution of distance between a virtual transcatheter ring at a size of the implanted device at the level of the coronary artery (VTC) in controls and in patients suffering coronary obstruction of the left coronary artery (LCA) and right coronary artery (RCA). The optimal cut-off level of 4 mm best predicts this complication for left coronary obstruction (area under the curve: 0.943; P < 0.001). All cases of RCA obstruction also occurred with concomitant LCA occlusion. 
Study limitations
Coronary angiograms leading to the diagnosis of coronary obstruction were analysed by the investigators of each centre. Pre-TAVR CT data were available in only part of the coronary obstruction patients and in a control group of 90 patients. While this represents only part of the entire cohort of the study, this is to date the largest pre-TAVR CT analysis in the context of aortic ViV procedures that was also entirely subject to centralized core laboratory analysis. 1, [17] [18] [19] [20] [21] The number of patients undergoing TAVR with the new retrievable and repositionable delivery systems was small, and precluded the performance a separate analysis of such THVs in the context of ViV procedures. Finally, future studies with a larger number of patients will have to confirm the VTC as significant factor related to coronary obstruction in ViV, and also further evaluate the cut-offs proposed herein.
In conclusion, the present study evaluating coronary obstruction as a complication of ViV procedures has shown that this is a rare but life-threatening complication that occurs more frequently in patients with stentless and stented bioprostheses with externally mounted leaflets, and in those with a short VTC. Despite successful treatment (mainly PCI) in most cases, haemodynamic support and conversion to open heart surgery were still required in a large proportion of patients, highlighting that such high-risk TAVR procedures should probably be performed in very experienced centres.
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